These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34862871)

  • 21. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
    Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
    BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
    Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
    Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs.
    Lee CH; Hötker AM; Voss MH; Feldman DR; Woo KM; Patil S; Coskey DT; Akin O; Hsieh JJ; Motzer RJ
    Clin Genitourin Cancer; 2016 Feb; 14(1):56-62. PubMed ID: 26404107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer.
    Zhao J; Yu H; Han T; Wang W; Tong W; Zhu X
    J BUON; 2019; 24(6):2267-2272. PubMed ID: 31983093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
    Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
    Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
    Papadimitriou M; Papadimitriou CA
    Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
    Scott LJ
    Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
    Curtit E; Thiery-Vuillemin A; Nguyen T; Heyd B; Pivot X; Di Martino V; Borg C
    J Clin Oncol; 2011 Apr; 29(12):e330-2. PubMed ID: 21263091
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeting angiogenesis in esophagogastric adenocarcinoma.
    Okines AF; Reynolds AR; Cunningham D
    Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of apatinib for the treatment of gastric cancer.
    Geng R; Song L; Li J; Zhao L
    Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis.
    Roviello G; Polom K; Roviello F; Marrelli D; Multari AG; Paganini G; Pacifico C; Generali D
    Cancer Invest; 2017 Mar; 35(3):187-194. PubMed ID: 28165839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of cardio-cerebrovascular adverse events in patients with brain metastasis from lung cancer treated with antiangiogenic drugs.
    Zhang Y; Zhang H; Song W
    Pak J Pharm Sci; 2022 Jan; 35(1):77-84. PubMed ID: 35221276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compounds in clinical Phase III and beyond.
    Kessler T; Bayer M; Schwöppe C; Liersch R; Mesters RM; Berdel WE
    Recent Results Cancer Res; 2010; 180():137-63. PubMed ID: 20033382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
    Scott AJ; Messersmith WA; Jimeno A
    Drugs Today (Barc); 2015 Apr; 51(4):223-9. PubMed ID: 26020064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
    Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.